[Skip to Navigation]
May 2017

Secukinumab for the Treatment of Deficiency of Interleukin 36 Receptor Antagonist in an Adolescent

Author Affiliations
  • 1Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • 2The Center for Genetic Diseases of the Skin and Hair, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • 3Faculty of Medicine, Hebrew University, Jerusalem, Israel
  • 4Jenin Health Directorate, Palestinian Ministry of Health, Palestinian Authority, West Bank
JAMA Dermatol. 2017;153(5):473-475. doi:10.1001/jamadermatol.2016.5705

Generalized pustular psoriasis (GPP) is a severe form of psoriasis. In a subset of patients with GPP, the disease results from deficiency of the interleukin (IL)-36 receptor antagonist (DITRA) due to mutations in the IL36RN gene (OMIM 614204). DITRA is characterized by episodic attacks of GPP associated with fever.1

Secukinumab, a recombinant, fully human IgG1κ monoclonal antibody inhibiting IL-17A and approved for the treatment of psoriasis vulgaris, was recently shown to be efficacious in patients with GPP.2 In this case report, we describe the efficacy of secukinumab treatment in an adolescent with DITRA.

Add or change institution